Literature DB >> 7858182

Humanization of the murine anti-human CD3 monoclonal antibody OKT3.

J R Adair1, D S Athwal, M W Bodmer, S M Bright, A M Collins, V L Pulito, P E Rao, R Reedman, A L Rothermel, D Xu.   

Abstract

OKT3 is a murine monoclonal antibody which recognizes an epitope on the epsilon-subunit within the human CD3 complex. OKT3 possesses potent immunosuppressive properties in vivo and has been proven effective in the treatment of renal, heart and liver allograft rejection. Despite its efficacy, significant problems remain associated with OKT3 therapy, i.e. T-cell activation and the anti-murine antibody response. To address the problem of the anti-murine antibody response we have constructed humanized versions of OKT3. One of the humanized derivatives, gOKT3-7 incorporating the OKT3 complementarity determining regions plus a small number of alterations to the human framework, has an affinity of 1.4 x 10(9) M-1 compared with 1.2 x 10(9) M-1 for the murine OKT3. A humanized antibody (gOKT3-1) incorporating only the CDRs from OKT3 was found to be functionally inactive, confirming the requirement for nonCDR substitutions. gOKT3-7 retains the ability of mOKT3 to induce T cell proliferation in vitro and appears to be a good candidate for further development for in vivo therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858182

Source DB:  PubMed          Journal:  Hum Antibodies Hybridomas        ISSN: 0956-960X


  21 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.

Authors:  Jing Li; Bo Zhou; Jianzhong Shentu; Li Du; Min Tan; Sheng Hou; Weizhu Qian; Bohua Li; Dapeng Zhang; Jianxin Dai; Hao Wang; Xu Zhang; Jianghua Chen; Yajun Guo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

3.  Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies.

Authors:  Leo Borras; Tea Gunde; Julia Tietz; Ulrich Bauer; Valérie Hulmann-Cottier; John P A Grimshaw; David M Urech
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

4.  Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Authors:  Brian H Santich; Jeong A Park; Hoa Tran; Hong-Fen Guo; Morgan Huse; Nai-Kong V Cheung
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

5.  Impact of lithium alone and in combination with antidepressants on cytokine production in vitro.

Authors:  Charlotte Petersein; Ulrich Sack; Roland Mergl; Jeremias Schönherr; Frank M Schmidt; Nicole Lichtblau; Kenneth C Kirkby; Katrin Bauer; Hubertus Himmerich
Journal:  J Neural Transm (Vienna)       Date:  2014-11-07       Impact factor: 3.575

6.  Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.

Authors:  Bohua Li; Hao Wang; Jianxin Dai; Junjie Ji; Weizhu Qian; Dapeng Zhang; Sheng Hou; Yajun Guo
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

7.  Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.

Authors:  Hong Xu; Ming Cheng; Hongfen Guo; Yuedan Chen; Morgan Huse; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2014-12-26       Impact factor: 11.151

8.  Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.

Authors:  Ming Cheng; Mahiuddin Ahmed; Hong Xu; Nai-Kong V Cheung
Journal:  Int J Cancer       Date:  2014-06-19       Impact factor: 7.396

9.  Characterization of a surrogate murine antibody to model anti-human CD3 therapies.

Authors:  Fabien Dépis; Eric Hatterer; Romain Ballet; Bruno Daubeuf; Laura Cons; Sophie Glatt; Walter Reith; Marie Kosco-Vilbois; Yann Dean
Journal:  MAbs       Date:  2013-04-18       Impact factor: 5.857

Review 10.  Immunogenicity of Protein Pharmaceuticals.

Authors:  Robert Dingman; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-12-30       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.